(firstQuint)Carboplatin and Gemcitabine With Bevacizumab Every 2 Weeks for Stage IIIb/IV Non-small Cell Lung Cancer.

 Treatment with Carboplatin and gemcitabine is one of the most active combination therapies used for first-line therapy of NSCLC.

 The optimum schedule for administration of carboplatin and gemcitabine is currently unknown.

 The addition of bevacizumab to another comparable platinum combination showed an overall survival advantage and a significantly greater response rate and progression-free survival.

.

 Carboplatin and Gemcitabine With Bevacizumab Every 2 Weeks for Stage IIIb/IV Non-small Cell Lung Cancer@highlight

The purpose of this study is to determine whether treatment with carboplatin and gemcitabine combined with bevacizumab every two weeks will provide increased survival.

